155 related articles for article (PubMed ID: 6543695)
21. Influence of ICRF 159 and trition WR 1339 on metastases of a rat epithelioma.
Pimm MV; Baldwin RW
Br J Cancer; 1975 Jan; 31(1):62-7. PubMed ID: 1156509
[TBL] [Abstract][Full Text] [Related]
22. Further evaluation of bimolane and analogs as potential antitumor agents.
Ren YF; Otter GM; Schmid FA
Eur J Cancer Clin Oncol; 1985 Apr; 21(4):493-7. PubMed ID: 3859415
[TBL] [Abstract][Full Text] [Related]
23. Effects of postsurgical immunotherapy with PGM in mice bearing Lewis lung carcinoma treated with p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt.
Sava G; Zorzet S; Perissin L; Lassiani L; Tomasic J
Methods Find Exp Clin Pharmacol; 1985 Sep; 7(9):477-80. PubMed ID: 4079598
[TBL] [Abstract][Full Text] [Related]
24. Antitumor and antimetastatic effects of benzenoid triazenes in mice bearing Lewis lung carcinoma.
Giraldi T; Guarino AM; Nisi C; Sava G
Pharmacol Res Commun; 1980 Jan; 12(1):1-11. PubMed ID: 7384159
[No Abstract] [Full Text] [Related]
25. Antitumor activity of DTIC (NSC-45388) in animals.
Venditti JM
Cancer Treat Rep; 1976 Feb; 60(2):135-40. PubMed ID: 1260771
[No Abstract] [Full Text] [Related]
26. Effects of antimetastatic, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice.
Sava G; Giraldi T; Perissin L; Zorzet S; Decorti G
Clin Exp Metastasis; 1987; 5(1):27-34. PubMed ID: 2951046
[TBL] [Abstract][Full Text] [Related]
27. Effect of stereoisomers related to ICRF-159 on metastasis of B16 melanoma.
Zwilling BS; Campolito LB; Reiches NA; George T; Witiak DT
Br J Cancer; 1981 Oct; 44(4):578-83. PubMed ID: 7295515
[TBL] [Abstract][Full Text] [Related]
28. Vascular changes in tumours after treatment with ICRF 159.
Le Serve AW; Hellmann K
Br J Pharmacol; 1971 Oct; 43(2):457P-458P. PubMed ID: 5158233
[No Abstract] [Full Text] [Related]
29. ICRF-187 in clinical oncology.
Poster DS; Penta JS; Bruno S; Macdonald JS
Cancer Clin Trials; 1981; 4(2):143-6. PubMed ID: 6788388
[TBL] [Abstract][Full Text] [Related]
30. Experimental studies at Southern Research Institute with DTIC (NSC-45388).
Montgomery JA
Cancer Treat Rep; 1976 Feb; 60(2):125-34. PubMed ID: 1260770
[TBL] [Abstract][Full Text] [Related]
31. Effect of high dose diethylstilbestrol and ICRF-159 on the growth and metastases of the R3327 MAT-LyLu prostate-derived tumor.
Heston WD; Kadmon D; Fair WR
Cancer Lett; 1981 Jul; 13(2):139-45. PubMed ID: 7306951
[TBL] [Abstract][Full Text] [Related]
32. Antineoplastic action of p-(3-methyl-1-triazeno)benzoic acid potassium salt, a monomethyl derivative of the antimetastatic compound DM-COOK.
Sava G; Zorzet S; Perissin L; Pacor S; Lassiani L; Nisi C; Varnavas A
Cancer Chemother Pharmacol; 1991; 27(6):423-8. PubMed ID: 2013112
[TBL] [Abstract][Full Text] [Related]
33. Editoral: ICRF 159.
Lancet; 1974 Mar; 1(7853):344-5. PubMed ID: 4131178
[No Abstract] [Full Text] [Related]
34. The effect of (+/-) 1,2-bis(3,5-dioxopiperazin-1-yl) propane (ICRF 159) on liver metastases from a hamster lymphoma.
Atherton A
Eur J Cancer (1965); 1975 Jun; 11(6):383-8. PubMed ID: 1174351
[No Abstract] [Full Text] [Related]
35. ICRF-159: current status and clinical prospects.
Bellet RE; Rozencweig M; Von Hoff DD; Penta JS; Wasserman TH; Muggia FM
Eur J Cancer (1965); 1977 Nov; 13(11):1293-8. PubMed ID: 590286
[No Abstract] [Full Text] [Related]
36. Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL).
Tentori L; Leonetti C; Lozupone F; Bonmassar E
Cancer Immunol Immunother; 1995 Dec; 41(6):375-83. PubMed ID: 8635195
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the R3327MAT-Lu prostatic tumor by diethylstilbestrol and 1,2-bis(3,5-dioxopiperazin-1-yl)propane.
Lazan DW; Heston WD; Kadmon D; Fair WR
Cancer Res; 1982 Apr; 42(4):1390-4. PubMed ID: 7060012
[TBL] [Abstract][Full Text] [Related]
38. Rotational stress reduces the effectiveness of antitumor drugs in mice.
Giraldi T; Perissin L; Zorzet S; Rapozzi V
Ann N Y Acad Sci; 1994 Nov; 741():234-43. PubMed ID: 7825811
[No Abstract] [Full Text] [Related]
39. DTIC (NSC-45388) in malignant melanoma: a perspective.
Comis RL
Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
[No Abstract] [Full Text] [Related]
40. ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.
Kovacs CJ; Evans MJ; Burholt DR; Schenken LL
Br J Cancer; 1979 May; 39(5):524-30. PubMed ID: 486308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
